TrialMolecular therapy : the journal of the American Society of Gene Therapy2017

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.

Karsten Geletneky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.